18+ Adults only. We do not sell to anyone under 18. Research compounds are supplied for research use only.
Peptide half-lives explained, with laboratory ampoules and vials

Peptide half-lives: why some are weekly and some are daily

Why is retatrutide once a week, while some peptides are researched once or even twice a day? The answer is a single number that sits behind almost every dosing question: half-life. Once you understand it, a lot of things about peptides, from how often they are used to why dose changes take weeks to settle, suddenly make sense.

Peptide half-lives in 60 seconds

  • Half-life is the time it takes for half of a compound to be cleared from the blood.
  • Your body’s own peptide hormones usually last minutes. Engineered versions can last days.
  • The tricks that stretch half-life include swapping vulnerable amino acids, attaching a fatty chain that rides on blood proteins, and making the molecule too big for the kidneys to filter quickly.
  • It takes roughly four to five half-lives to reach a steady level, which is why weekly compounds need about a month to settle after a dose change.

What half-life actually means

After a dose, the level of a compound in the blood rises, peaks and then falls as the body breaks it down and clears it. Half-life is how long that fall takes to halve the level. After one half-life, half is left; after two, a quarter; after five, only about 3%.

It decides two practical things. First, how often a compound needs to be given to keep a steady effect. Second, how long it takes to settle after you start or change the dose, because each new dose stacks on what is left of the last one until the amount going in matches the amount being cleared.

The GLP-1 story: from two minutes to a week

Half-lives compared: natural GLP-1 about two minutes, liraglutide about 13 hours, tirzepatide about five days and semaglutide about a week

GLP-1 is the clearest example of how much engineering can change a half-life. The hormone your gut releases after eating lasts about two minutes in the blood. An enzyme called DPP-4 chops it up almost immediately, and the kidneys clear the rest. That is fine for a natural signal after a meal, and useless for a weekly treatment.

The compounds that followed stretched that window step by step:

  • Liraglutide added a fatty chain that lets it bind to albumin, the most common protein in blood. Bound to albumin, it is shielded from breakdown and from the kidneys, giving a half-life of about 13 hours, enough for once-daily use.
  • Semaglutide swapped the amino acid DPP-4 attacks for one it cannot cut and used a longer fatty chain that binds albumin more tightly. The result is a half-life of about a week, which is why it is used once weekly.
  • Tirzepatide and retatrutide use similar albumin-binding designs and sit in the five to six day range, also once weekly.

How engineering stretched GLP-1

  1. Natural GLP-1: about 2 minutes
  2. Liraglutide: fatty chain binds albumin, about 13 hours
  3. Semaglutide: longer chain, about a week
  4. Tirzepatide and retatrutide: five to six days

Why a weekly compound takes a month to settle

Because it takes four to five half-lives to reach a steady level, a compound with a one-week half-life needs roughly four to five weeks before the level in the blood stops climbing. This is a big part of why the major GLP-1 trials increased doses every four weeks, and why judging a dose after one or two injections tells you very little. We cover the escalation schedules in why GLP-1 doses start low.

The growth hormone peptides: why “DAC” matters

The same principle explains one of the most confusing names in the peptide world. CJC-1295 comes in two versions:

  • Without DAC (also called modified GRF 1-29): a half-life of roughly half an hour. It produces a short, sharp pulse of growth hormone, closer to the body’s natural rhythm, and is usually researched once or more a day, often paired with ipamorelin.
  • With DAC (Drug Affinity Complex): a chemical tag that binds albumin, stretching the half-life to roughly a week and producing a much longer, flatter rise in growth hormone.

Neither is simply better. They are different tools, and knowing which one you are looking at matters. Our Night Surge pen uses CJC-1295 without DAC together with ipamorelin, the pulse-style pairing. Tesamorelin and sermorelin, also GHRH analogues, sit in the short half-life group too.

Half-life is not the same as how long it works

One caution. A short half-life does not always mean a short effect. A peptide that triggers a pulse of growth hormone may be cleared within an hour while the downstream effects last much longer. And for many research peptides, BPC-157 among them, the half-life in humans has simply not been properly measured. Where a number exists, it is a guide to dosing frequency, not a full description of what a compound does.

Frequently asked questions

What is a peptide’s half-life?

It is the time it takes for the level of the peptide in the blood to fall by half. It decides how often a compound needs to be given and how long it takes to reach a steady level.

Why is semaglutide once a week when natural GLP-1 lasts minutes?

Semaglutide was engineered to resist the enzyme that breaks GLP-1 down and to bind albumin in the blood, which protects it from breakdown and kidney clearance. That stretches its half-life to about a week.

How long does a weekly peptide take to reach a steady level?

Roughly four to five half-lives, so about four to five weeks for a compound with a one-week half-life. That is why dose changes in the trials were made every four weeks.

What is the difference between CJC-1295 with and without DAC?

Without DAC, CJC-1295 has a half-life of about half an hour and produces a short pulse of growth hormone. With DAC, a tag that binds albumin stretches it to about a week, producing a longer, flatter rise.

Sources

  • Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry, 2015.
  • Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews, 2007.
  • Teichman SL et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting analog of GHRH. Journal of Clinical Endocrinology and Metabolism, 2006.

This article is for educational purposes only and is not medical advice. The research compounds discussed are sold for research use. Our guide to what research use only actually means explains the label.

Related reading: HGH peptides and growth hormone.

For how the weekly GLP-1s compare, read retatrutide vs tirzepatide vs semaglutide. If you are converting a milligram dose to clicks or units, the peptide calculator does the arithmetic.